Rat ALK-7 Alexa Fluor® 700-conjugated Antibody

Applications

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Preparation and Storage

Background: ALK-7

Transforming growth Factor beta (TGF-beta ) superfamily ligands exert their biological activities via binding to heteromeric receptor complexes of two types (I and II) of serine/threonine kinases. Type II receptors are constitutively active kinases that phosphorylate type I receptors upon ligand binding. In turn, activated type I kinases phosphorylate downstream signaling molecules including the various smads. Transmembrane proteoglycans, including the type III receptor (betaglycan) and endoglin, can bind and present some of the TGF-beta superfamily ligands to type I and II receptor complexes and enhance their cellular responses. Seven type I receptors (also termed activin receptor-like kinase (ALK)) and five type II receptors have been isolated from mammals. ALK-2, -3, -4, -5, and -6 are also known as Activin R1A, BMPR-1A, Activin R1B, TGF-beta R1, and BMPR-1B, respectively, reflecting their ligand preferences. ALK-7 shares with other type I receptors a cysteine-rich domain with conserved cysteine spacing in the extracellular region, and a glycine-and serine-rich domain (the GS domain) preceding the kinase domain. Rat ALK-7 expression is restricted to the adult central nervous system, suggesting a possible role of ALK-7 during postnatal maturation and maintenance of several neuronal subpopulations in the cerebellum.

Product Datasheets

Related Research Areas

• TGF-beta Family
• TGF-beta Superfamily